These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29138653)

  • 21. Predictors of adverse drug reaction among adult HIV-infected patients on antiretroviral therapy in government hospitals of Kaffa Zone, Ethiopia; November 2018: a retrospective cohort.
    Mitkie AA; Bekele FB; Debiso AT
    Pan Afr Med J; 2021; 38():181. PubMed ID: 33995787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.
    Kalemeera F; Mbango C; Mubita M; Naikaku E; Gaida R; Godman B
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):777-83. PubMed ID: 27309846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnitude of adverse drug reaction and associated factors among HIV-infected adults on antiretroviral therapy in Hiwot Fana specialized university hospital, eastern Ethiopia.
    Weldegebreal F; Mitiku H; Teklemariam Z
    Pan Afr Med J; 2016; 24():255. PubMed ID: 27800108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of haematological changes after switching from stavudine to zidovudine-based antiretroviral treatment in HIV-infected children.
    Singh A; Hemal A; Agarwal S; Dubey NK; Buxi G
    Int J STD AIDS; 2016 Nov; 27(13):1145-1152. PubMed ID: 24516076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
    Bender MA; Kumarasamy N; Mayer KH; Wang B; Walensky RP; Flanigan T; Schackman BR; Scott CA; Lu Z; Freedberg KA
    Clin Infect Dis; 2010 Feb; 50(3):416-25. PubMed ID: 20043752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
    Menezes CN; Crowther NJ; Duarte R; Van Amsterdam D; Evans D; Dickens C; Dix-Peek T; Rassool M; Prinsloo A; Raal F; Sanne I
    HIV Med; 2014 Jan; 15(1):3-12. PubMed ID: 23980620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
    van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
    Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
    Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2010 Jan; 170(1):57-65. PubMed ID: 20065200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
    Yu XD; Huang H; Jiao Y; Li J; Fan X; Zhang D; Wang FS
    Lipids Health Dis; 2023 Feb; 22(1):27. PubMed ID: 36823632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
    Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
    AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
    Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
    AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.
    Becker SL; Raffanti SR; Hansen NI; Fusco JS; Fusco GP; Slatko GH; Igboko EF; Graham NM;
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):72-81. PubMed ID: 11176271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.